[vc_row full_width=”stretch_row” css=”.vc_custom_1531732107238{background-color: #fcc118 !important;}”][vc_column]

[/vc_column][/vc_row][vc_row css=”.vc_custom_1531730959461{border-bottom-width: 1px !important;background-color: #f9fafb !important;border-bottom-color: #eef3f7 !important;border-bottom-style: solid !important;}”][vc_column css=”.vc_custom_1531891416301{margin-bottom: 0px !important;}”][bsfp-cryptocurrency style=”widget-6″ align=”auto” columns=”2″ scheme=”light” coins=”top-x-coins” coins-count=”8″ coins-selected=”” currency=”USD” title=”Cryptocurrencies” show_title=”0″ icon=”” heading_color=”” heading_style=”default” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ css=”.vc_custom_1531730265600{margin-bottom: 0px !important;}” custom-css-class=”” custom-id=””][/vc_column][/vc_row]

AMGN Earnings: Everything you need to know about Amgen’s Q1 results


Amgen Inc. (NASDAQ: AMGN) has reported lower revenues and adjusted earnings for the first quarter of 2023. The biotechnology firm also provided guidance for fiscal 2023.

Unadjusted earnings decreased to $3.98 per share in the March quarter from $4.25 per share in the year-ago period. The reported net income was $2.84 billion or $5.28 per share in the latest quarter, compared to $1.48 billion or $2.68 per share in the same period of last year.

Total revenues edged down by 2% from last year to $6.11 billion during the three-month period. A 2% increase in product sales was more than offset by a decline in Other Revenue from the company’s COVID-19 manufacturing collaboration.

Prior performance

Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More